Peter Virsik - ESSA Pharma COO, Executive Vice President
| EPIX Stock | USD 6.25 0.15 2.34% |
President
Mr. Peter Virsik is Chief Operating Officer, Executive Vice President of the Company. Prior to joining Essa, Mr. Virsik served as senior vicepresident, corporate development, for XenoPort, leading licensing, strategy, new product planning and alliance management for the company. During his tenure at XenoPort, Mr. Virsik played an integral role in the licensing and commercialization of Horizant . Prior to XenoPort, Mr. Virsik worked for Gilead Sciences from 2000 through 2005 in corporate development, where he was involved in building Gilead HIV franchise through the acquisition of Triangle Pharmaceuticals and the licensing of Vitekta . Before joining Gilead, Mr. Virsik worked at J.P. Morgan in the biotechnology equity research group and as a consultant for Ernst and Young. Mr. Virsik began his career in research and development at Genentech. since 2016.
| Tenure | 8 years |
| Address | 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5 |
| Phone | 778 331 0962 |
| Web | https://www.essapharma.com |
Latest Insider Transactions
Peter Virsik Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Virsik against ESSA Pharma stock is an integral part of due diligence when investing in ESSA Pharma. Peter Virsik insider activity provides valuable insight into whether ESSA Pharma is net buyers or sellers over its current business cycle. Note, ESSA Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell ESSA Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Virsik over a month ago Disposition of 694 shares by Peter Virsik of ESSA Pharma at 8.98 subject to Rule 16b-3 | ||
Peter Virsik over two months ago Exercise or conversion by Peter Virsik of 72782 shares of ESSA Pharma subject to Rule 16b-3 | ||
Peter Virsik over three months ago Sale by Peter Virsik of 699 shares of ESSA Pharma |
ESSA Pharma Management Efficiency
The company has return on total asset (ROA) of (0.1287) % which means that it has lost $0.1287 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1705) %, meaning that it created substantial loss on money invested by shareholders. ESSA Pharma's management efficiency ratios could be used to measure how well ESSA Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.17 in 2024. At this time, ESSA Pharma's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 201.8 M in 2024, whereas Other Current Assets are likely to drop slightly above 639.6 K in 2024.Similar Executives
| Found 7 records | PRESIDENT Age | ||
| Hendra Surya | Summit Therapeutics PLC | 44 | |
| Darjoto Setyawan | Summit Therapeutics PLC | 58 | |
| Timothy Keutzer | Spero Therapeutics | 56 | |
| Stephen Garbacz | Spero Therapeutics | 56 | |
| Thomas Meyer | Altamira Therapeutics | 56 | |
| David Roblin | Summit Therapeutics PLC | N/A | |
| Roza Putra | Summit Therapeutics PLC | N/A | |
Management Performance
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.13 |
ESSA Pharma Leadership Team
Elected by the shareholders, the ESSA Pharma's board of directors comprises two types of representatives: ESSA Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ESSA. The board's role is to monitor ESSA Pharma's management team and ensure that shareholders' interests are well served. ESSA Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ESSA Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Wood, CFO | ||
| Erin Rudsinski, Executive | ||
| CMA CPA, Chief Officer | ||
| Gary Sollis, Independent Director | ||
| Neil Thapar, Executive | ||
| Marianne Sadar, Chief Scientific Officer and Director | ||
| Franklin Berger, Independent Director | ||
| Alessandra MD, Chief Officer | ||
| Frank Perabo, Chief Medical Officer | ||
| Erica Osbourne, Executive | ||
| Steve Pondell, Executive | ||
| Raymond Andersen, Chief Technical Officer, Secretary and Director | ||
| Terry Schuenemeyer, Executive | ||
| David Parkinson, Independent Director | ||
| Richard Glickman, Independent Chairman of the Board | ||
| MS MBA, Executive COO | ||
| Nkengyal Barber, Executive | ||
| Scott Requadt, Director | ||
| Peter Virsik, COO, Executive Vice President | ||
| Otello Stampacchia, Director | ||
| Chandtip Chandhasin, Executive | ||
| Loleta Harris, Executive | ||
| David MD, CEO and President and Director |
ESSA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ESSA Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 141.38 M | ||||
| Shares Outstanding | 44.24 M | ||||
| Shares Owned By Insiders | 2.20 % | ||||
| Shares Owned By Institutions | 78.71 % | ||||
| Number Of Shares Shorted | 802.84 K | ||||
| Price To Earning | (1.12) X | ||||
| Price To Book | 2.48 X | ||||
| EBITDA | (26.46 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ESSA Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ESSA Pharma's short interest history, or implied volatility extrapolated from ESSA Pharma options trading.
Pair Trading with ESSA Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ESSA Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ESSA Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against ESSA Stock
| 0.59 | ELYM | Eliem Therapeutics | PairCorr |
| 0.55 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.5 | CGC | Canopy Growth Corp Trending | PairCorr |
The ability to find closely correlated positions to ESSA Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ESSA Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ESSA Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ESSA Pharma to buy it.
The correlation of ESSA Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ESSA Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ESSA Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ESSA Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for ESSA Stock analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is ESSA Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ESSA Pharma. If investors know ESSA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ESSA Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Return On Assets (0.13) | Return On Equity (0.17) |
The market value of ESSA Pharma is measured differently than its book value, which is the value of ESSA that is recorded on the company's balance sheet. Investors also form their own opinion of ESSA Pharma's value that differs from its market value or its book value, called intrinsic value, which is ESSA Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ESSA Pharma's market value can be influenced by many factors that don't directly affect ESSA Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ESSA Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ESSA Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ESSA Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.